This report was first published by Endpoints News. To see the original version, click here
Another key player in China’s biotech ecosystem has landed a pharma deal.
On Sunday, Eli Lilly and Insilico Medicine announced a drug discovery collaboration, with the Indianapolis drugmaker paying $115 million upfront to exclusively license undisclosed preclinical programs and work with Insilico on some undisclosed targets. The deal carries potential milestone payments valued at up to $2.75 billion.
您已阅读20%（492字），剩余80%（2003字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。